Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 3 Recruiting 224 enrolled Chipscreen Biosciences, Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype

Timeline

Start: 2025-08-12
Primary completion: 2032-12
Completion: 2032-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tucidinostat	Small molecule	—	Oral
Background	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Background	Doxorubicin	Other / unclassified	70 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	100 mg	Oral
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Summary

Timeline

Drugs

Indications